Compare PUMP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PUMP | OMER |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 844.6M |
| IPO Year | 2017 | 2008 |
| Metric | PUMP | OMER |
|---|---|---|
| Price | $10.17 | $17.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $14.14 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.5M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | ★ $1,269,158,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.61 | $233.22 |
| P/E Ratio | ★ N/A | $22.30 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.64 | $3.94 |
| 52 Week High | $18.50 | $19.65 |
| Indicator | PUMP | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 49.27 |
| Support Level | $10.28 | $10.16 |
| Resistance Level | $10.55 | $17.65 |
| Average True Range (ATR) | 0.54 | 0.82 |
| MACD | -0.04 | -0.45 |
| Stochastic Oscillator | 5.83 | 21.47 |
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.